synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
==== Dunwall ==== Antonov was the principal designer of the city of Dunwall, Dishonored's steampunk dystopian setting described as an "oily" labyrinth of brickwork buildings. The city, whose economy is centered around the whaling industry, is governed by an authoritarian monarchist regime filled with officials too "callous" to deal with its residents' problems. During the events of the game, Dunwall is experiencing a plague virus which originated from its overwhelming rat population. It has significant wealth inequality, and the plague has trapped its lower class inside the city, "condemned to die by either an infection in the body or a knife in the heart", Levi Winslow writes for Kotaku. The city features a mix of Victorian and Gothic architecture, and was inspired by British cities, mainly London and Edinburgh, as they were from the mid-1800s to 1930. Antonov stated that that Britain is "both exotic and familiar to Americans and to Europeans, so it was just about perfect".
=== Environmental chemistry === An important goal of environmental chemistry is tracing the source and degradation of pollutants. Various methods have been used for fingerprinting pools of environmental pollutants such as the bulk chemical composition of a spill, isotope ratios of the bulk chemical mixture, or isotope ratios of individual constituent compounds. Stable isotopes of carbon and hydrogen can be used as complementary fingerprinting techniques for natural gas. The DHR of hydrocarbons from the Deepwater Horizon oil spill was used to verify that they were likely from the Macondo well. HICs have also been used as a measure of the relative amount of biodegradation that has occurred in oil reservoirs in China, and studies on pure cultures of n-alkane degrading organisms have shown a chain-length dependence on the amount of hydrogen isotope fractionation during degradation. Additional studies have also shown hydrogen isotope effects in the degradation of methyl tert-butyl ether and toluene that have been suggested to be useful in the evaluation of the level of degradation of these polluting compounds in the environment. In both cases the residual unreacted compounds became 2H-enriched to a few tens of ‰, with variations exhibited between different organisms and degree of reaction completeness. These observations of heavy residual compounds have been applied to field observations of biodegradation reactions such as removal of benzene and ethylbenzene, which imparted a D/H fractionation of 27 and 50 ‰, respectively.
hENT3 is expressed highly in the cerebral cortex, lateral ventricle, ovary and adrenal gland. hENT4 is more commonly known as the plasma membrane monoamine transporter (PMAT), as it facilitates the movement of organic cations and biogenic amines across the membrane.
== Selected-ion monitoring chromatogram (SIM) == A selected-ion monitoring (SIM) chromatogram is similar to an EIC/XIC, with the exception that the mass spectrometer is operated in SIM mode, such that only preselected m/z values are detected in the analysis. SIM experiments can be performed using mass spectrometry (MS) or tandem mass spectrometry (MS/MS) instruments. They are more common on MS instruments. This differs significantly from the extracted-ion chromatogram mentioned above in that only data for the ion(s) of interest are collected in a SIM experiment; for extracted-ion chromatograms (EIC or XIC), data for an entire mass range are collected during the run and then examined for analytes of interest after the completion of the run.
=== Atrial Natriuretic Peptide (ANP) === The human gene that makes ANP is called NPPA, and it's on chromosome 1 at location 1p36.21. The gene is about two kilobases long and has three parts called exons and two called introns. The mRNA from this gene makes a protein called preproANP with 151 parts called amino acids. The first 25 parts are removed to create a 126-part protein called proANP which is stored in the atrial granules. When the body needs ANP, Corin (an enzyme) breaks apart proANP to make the active form of ANP, which is 28 amino acids long.
Sources: en.wikipedia.org
He found chloramines to be the best, for being stable, non-toxic, and not very irritating, yet powerful bactericides, presumably due to their release of hypochlorous acid. However, the difficulty of procuring them led him to choose "hypochlorite of soda" as a practical alternative. Between the two World Wars, the preparation was often called "Carrel–Dakin solution," even though Dakin did the bulk of the research work that led to its formulation. The name of Carrel was dropped after World War II, presumably due to his active involvement in eugenics movements and the advocacy of elimination of "inferior" humans. Since penicillin became established as an antibiotic in 1943, use of Dakin's solution and other topical antiseptics for wound treatment has declined, and their use is frowned upon in modern medical care. However, the solution continues to be used (as of 2023) due to its broad activity against aerobic and anaerobic organisms, including fungi and antibiotic-resistant organisms, its very low cost, and its wide availability. In emergency situations, it can be produced on the field from liquid bleach and sodium bicarbonate.
=== Microorganisms in kimchi === The microorganisms present in kimchi include Bacillus mycoides, B. pseudomycoides, B. subtilis, Lactobacillus brevis, Lb. curvatus, Lb. kimchii, Lb. parabrevis, Lb. pentosus, Lb. plantarum, Lb. sakei, Lb. spicheri, Lactococcus carnosum, Lc. gelidum, Lc. lactis, Leuconostoc carnosum, Ln. citreum, Ln. gasicomitatum, Ln. gelidum, Ln. holzapfelii, Ln. inhae, Ln. kimchii, Ln. lactis, Ln. mesenteroides, Serratia marcescens, Weissella cibaria, W. confusa, W. kandleri, W. kimchii. W. koreensis, and W. soli. Archaea and yeasts, such as Saccharomyces, Candida, Pichia, and Kluyveromyces are also present in kimchi, with the latter being responsible for undesirable white colonies that sometimes form in the product as well as food spoilages and off-flavors. In early fermentation stages, the Leuconostoc variety is found more dominantly in kimchi fermentation because of its lower acid tolerance and microaerophilic properties; the Leuconostoc variety also grows better at low salt concentrations. Throughout the fermentation process, as acidity rises, the Lactobacillus and Weissella variety become dominant because of their higher acid tolerance. Lactobacillus also grows better in conditions with a higher salt concentration. These microorganisms are present due to the natural microflora provided by utilizing unsterilized food materials in the production of kimchi.
Src homology 2 (SH2) domain SH2 domains are structurally composed by three-stranded twisted beta sheet sandwiched flanked by two alpha-helices. The existence of a deep binding pocket with high affinity for phosphotyrosine, but not for phosphoserine or phosphothreonine, is essential for the recognition of tyrosine phosphorylated proteins, mainly autophosphorylated growth factor receptors. Growth factor receptor binding proteins and phospholipase Cγ are examples of proteins that have SH2 domains. Src homology 3 (SH3) domain Structurally, SH3 domains are constituted by a beta barrel formed by two orthogonal beta sheets and three anti-parallel beta strands. These domains recognize proline enriched sequences, as polyproline type II helical structure (PXXP motifs) in cell signaling proteins like protein tyrosine kinases and the growth factor receptor bound protein 2 (Grb2). Phosphotyrosine-binding (PTB) domain PTB domains interact with sequences that contain a phosphotyrosine group. These domains can be found in the insulin receptor substrate. LIM domain LIM domains were initially identified in three homeodomain transcription factors (lin11, is11, and mec3). In addition to this homeodomain proteins and other proteins involved in development, LIM domains have also been identified in non-homeodomain proteins with relevant roles in cellular differentiation, association with cytoskeleton and senescence. These domains contain a tandem cysteine-rich Zn2+-finger motif and embrace the consensus sequence CX2CX16-23HX2CX2CX2CX16-21CX2C/H/D.
== Areas of application and limits == First used in theoretical physics, the molecular dynamics method gained popularity in materials science soon afterward, and since the 1970s it has also been commonly used in biochemistry and biophysics. MD is frequently used to refine 3-dimensional structures of proteins and other macromolecules based on experimental constraints from X-ray crystallography or NMR spectroscopy. In physics, MD is used to examine the dynamics of atomic-level phenomena that cannot be observed directly, such as thin film growth and ion subplantation, and to examine the physical properties of nanotechnological devices that have not or cannot yet be created. In biophysics and structural biology, the method is frequently applied to study the motions of macromolecules such as proteins and nucleic acids, which can be useful for interpreting the results of certain biophysical experiments and for modeling interactions with other molecules, as in ligand docking. In principle, MD can be used for ab initio prediction of protein structure by simulating folding of the polypeptide chain from a random coil. MD can also be used to compute other thermodynamic properties such as drug solubilities and free energies of solvation including in polymers. The results of MD simulations can be tested through comparison to experiments that measure molecular dynamics, of which a popular method is NMR spectroscopy.
Sherman (1930–2008), 12 US patents John Sherwood (died 2020), British physical chemist Nevil Vincent Sidgwick (1873–1952), English theoretical chemist, known for work in valency Osamu Shimomura (1928–2018), 2008 Nobel Prize in Chemistry Hideki Shirakawa (1936–2026), 2000 Nobel Prize in Chemistry Alexander Shulgin (1925–2014), pioneer researcher in Psychopharmacology and Entheogens Salimuzzaman Siddiqui (1897–1994), Pakistani chemist, pioneer in natural products chemistry Oktay Sinanoglu (1935–2015), Turkish chemist Joseph H. Simons (1897–1983), U.S. chemist, discoverer of fluorocarbons, used in gaseous diffusion of Uranium for Manhattan project Jens Christian Skou (1918–2018), 1997 Nobel Prize in Chemistry Richard Smalley (1943–2005), 1996 Nobel Prize in Chemistry Michael Smith (1932–2000), 1993 Nobel Prize in Chemistry Ascanio Sobrero (1812–1888), Italian chemist, discoverer of nitroglycerin Frederick Soddy (1877–1956), British chemist, 1921 Nobel Prize in Chemistry Susan Solomon (born 1956), American atmospheric chemist Ernest Solvay (1838–1922), Belgian chemist and industrialist S.P.L. Sørensen (1868–1939), Danish chemist Gabor A.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.